DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

Phase 2

Completed

Conditions: Parkinson Disease

First Posted Date: 2005-09-08

Last Posted Date: 2013-10-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 254

Registration Number: NCT00148512

Locations: 🇩🇪
Paracelsus-Elena-Klinik, Kassel, Germany
🇦🇹
Univ.-Klinik für Neurologie, Innsbruck, Austria
🇫🇷
Hôpital Gabriel Montpied, Clermont Ferrand, France

and more 37 locations

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir

First Posted Date: 2005-09-07

Last Posted Date: 2014-03-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 997

Registration Number: NCT00146328

Locations: 🇺🇸
1182.17.26 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
🇺🇸
1182.17.89 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸
1182.17.73 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States

and more 230 locations

The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

Phase 2

Completed

Conditions: Insulin Resistance
Obesity

First Posted Date: 2005-09-07

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 138

Registration Number: NCT00146289

Locations: 🇨🇦
St. Joseph's Health Care London, London, Ontario, Canada
🇩🇪
Universitätsmedizin Berlin, Berlin, Germany
🇩🇪
Boehringer Ingelheim Investigational Site, Unterschneidheim, Germany

and more 8 locations

Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-09-07

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 345

Registration Number: NCT00146341

Locations: 🇨🇳
Ruijin Hospital, School of Medicine, Shanghai, China
🇨🇳
No. 1 Hosp Affiliated to Med College, Zhejiang Province, China
🇨🇳
Beijing Tiantan Hospital, Beijing, China

and more 6 locations

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir (with low dose ritonavir)
Drug: Comparator protease inhibitor(CPI)/low dose ritonavir(r)

First Posted Date: 2005-09-05

Last Posted Date: 2014-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 882

Registration Number: NCT00144170

Locations: 🇲🇽
1182.48.5202 Hospital Lopez Mateos, Mexico, Mexico
🇵🇹
1182.48.3505 Hospital Egas Moniz, Lisboa, Portugal
🇲🇽
1182.48.5201 Centro Médico La Raza IMSS, Mexico, D.F., Mexico

and more 171 locations

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-09-05

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5993

Registration Number: NCT00144339

Locations: 🇺🇸
205.235.3781 Boehringer Ingelheim Investigational Site, San Diego, California, United States
🇺🇸
205.235.3782 Boehringer Ingelheim Investigational Site, Fredericksburg, Virginia, United States
🇺🇸
205.235.3744 Boehringer Ingelheim Investigational Site, Danville, Virginia, United States

and more 487 locations

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 218

Registration Number: NCT00144222

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan

Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 255

Registration Number: NCT00144287

Locations: 🇩🇪
Epimed GmbH, Berlin, Germany
🇩🇪
Städtisches Klinikum St. Georg, Leipzig, Germany
🇩🇪
Johannes-Gutenberg-Universität Mainz, Mainz, Germany

and more 25 locations

A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

Phase 3

Completed

Conditions: Acquired Immunodeficiency Syndrome

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 407

Registration Number: NCT00144183

Locations: 🇿🇦
Boehringer Ingelheim Investigational Site, Soweto, South Africa

12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-09-05

Last Posted Date: 2023-12-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 224

Registration Number: NCT00144196

Locations: 🇸🇪
Boehringer Ingelheim Investigational Site, Uppsala, Sweden
🇸🇪
Jakobsbergs sjukhus, Birgittavagen 4, Jarfalla, Sweden
🇸🇪
KvartersAkuten, Timmermansgatan 26, Lule?, Sweden

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy